Towards Estimation of HIV-1 Date of Infection: A Time-Continuous IgG-Model Shows That Seroconversion Does Not Occur at the Midpoint between Negative and Positive Tests

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Skar, Helena ^a   Albert, Jan ^b,c   Leitner, Thomas ^a  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G;

ARTICLE; BED ENZYME IMMUNOASSAY; CONTROLLED STUDY; DATE OF INFECTION; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE SURVEILLANCE; ENZYME IMMUNOASSAY; ETHNIC GROUP; HEALTH SURVEY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGLOBULIN PRODUCTION; MAJOR CLINICAL STUDY; POPULATION RESEARCH; SEROCONVERSION; STATISTICAL MODEL; SWEDISH; VALIDATION STUDY;

FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN G; MALE; MODELS, THEORETICAL; TIME FACTORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84876183014     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060906     Document Type: Article

References (52)

1. Incidence Assay Critical Path Working Group (2011) More and better information to tackle HIV epidemics: towards improved HIV incidence assays. PLoS medicine 8: e1001045.
2. UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance (2011) When and how to use assays for recent infection to estimate HIV incidence at a population level. Geneva, Switzerland: World Health Organization.
3. Busch MP, Pilcher CD, Mastro TD, Kaldor J, Vercauteren G, et al. (2010) Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS 24: 2763-2771.
4. Murphy G, Parry JV (2008) Assays for the detection of recent infections with human immunodeficiency virus type 1. Euro Surveill 13.
5. Park SY, Love TM, Nelson J, Thurston SW, Perelson AS, et al. (2011) Designing a genome-based HIV incidence assay with high sensitivity and specificity. AIDS 25: F13-19.
6. Le Vu S, Pillonel J, Semaille C, Bernillon P, Le Strat Y, et al. (2008) Principles and uses of HIV incidence estimation from recent infection testing-a review. Euro surveillance: bulletin europeen sur les maladies transmissibles = European communicable disease bulletin 13.
7. Hallett TB, (2011) Estimating the HIV incidence rate: recent and future developments. Current opinion in HIV and AIDS 6: 102-107.
8. Laeyendecker O, Brookmeyer R, Cousins MM, Mullis CE, Konikoff J, et al. (2012) HIV Incidence Determination in the United States: A Multi-Assay Approach. The Journal of infectious diseases.
9. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, et al. (2003) Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17: 1871-1879.
10. Cohen MS, Shaw GM, McMichael AJ, Haynes BF, (2011) Acute HIV-1 Infection. The New England Journal of Medicine 364: 1943-1954.
11. Guy R, Gold J, Calleja JM, Kim AA, Parekh B, et al. (2009) Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review. Lancet Infect Dis 9: 747-759.
12. Janssen RS, Satten GA, Stramer SL, Rawal BD, O'Brien TR, et al. (1998) New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 280: 42-48.
13. Dobbs T, Kennedy S, Pau CP, McDougal JS, Parekh BS, (2004) Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. Journal of Clinical Microbiology 42: 2623-2628.
14. Barin F, Meyer L, Lancar R, Deveau C, Gharib M, et al. (2005) Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots. J Clin Microbiol 43: 4441-4447.
15. Murphy G, Parry JV (2008) Assays for the detection of recent infections with human immunodeficiency virus type 1. Euro surveillance: bulletin europeen sur les maladies transmissibles = European communicable disease bulletin 13.
16. Hargrove JW, Humphrey JH, Mutasa K, Parekh BS, McDougal JS, et al. (2008) Improved HIV-1 incidence estimates using the BED capture enzyme immunoassay. AIDS 22: 511-518.
17. McDougal JS, Parekh BS, Peterson ML, Branson BM, Dobbs T, et al. (2006) Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay. AIDS Res Hum Retroviruses 22: 945-952.
18. Parekh BS, Hanson DL, Hargrove J, Branson B, Green T, et al. (2011) Determination of mean recency period for estimation of HIV type 1 Incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Research and Human Retroviruses 27: 265-273.
19. Duong YT, Qiu M, De AK, Jackson K, Dobbs T, et al. (2012) Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS ONE 7: e33328.
20. Ragonnet-Cronin M, Aris-Brosou S, Joanisse I, Merks H, Vallee D, et al. (2012) Genetic diversity as a marker for timing infection in HIV-infected patients: evaluation of a 6-month window and comparison with BED. The Journal of infectious diseases 206: 756-764.
21. Karlsson A, Bjorkman P, Bratt G, Ekvall H, Gisslen M, et al. (2012) Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010. PLoS ONE: in press.
22. Parekh BS, Kennedy MS, Dobbs T, Pau CP, Byers R, et al. (2002) Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Research and Human Retroviruses 18: 295-307.
23. Pinheiro J, Bates D, DebRoy S, Sarkar D, the R Core team (2012) nlme: Linear and nonlinear mixed effects models. 3.1-103 ed.
24. Bates D, Maechler M, Bolker B (2011) lme4: Linear mixed-effects models using S4 classes. 0.999375-42 ed.
25. R Development Core Team (2003) R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing.
26. Karita E, Price M, Hunter E, Chomba E, Allen S, et al. (2007) Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa. AIDS 21: 403-408.
27. Song R, Karon JM, White E, Goldbaum G, (2006) Estimating the distribution of a renewal process from times at which events from an independent process are detected. Biometrics 62: 838-846.
28. Skar H, Axelsson M, Berggren I, Thalme A, Gyllensten K, et al. (2011) Dynamics of two separate but linked HIV-1 CRF01_AE outbreaks among injection drug users in Stockholm, Sweden, and Helsinki, Finland. Journal of Virology 85: 510-518.
29. Von Gegerfelt A, Albert J, Morfeldt-Manson L, Broliden K, Fenyo EM, (1991) Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease. Virology 185: 162-168.
30. Fisher M, Pao D, Murphy G, Dean G, McElborough D, et al. (2007) Serological testing algorithm shows rising HIV incidence in a UK cohort of men who have sex with men: 10 years application. AIDS 21: 2309-2314.
31. Batzing-Feigenbaum J, Kollan C, Kuhne A, Matysiak-Klose D, Gunsenheimer-Bartmeyer B, et al. (2011) Cohort profile: the German ClinSurv HIV project-a multicentre open clinical cohort study supplementing national HIV surveillance. HIV medicine 12: 269-278.
32. Sharma U, Schito M, Welte A, Rousseau C, Fitzgibbon J, et al. (2011) Novel Biomarkers for HIV Incidence Assay Development. AIDS Research and Human Retroviruses.
33. Sommen C, Commenges D, Vu SL, Meyer L, Alioum A, (2011) Estimation of the distribution of infection times using longitudinal serological markers of HIV: implications for the estimation of HIV incidence. Biometrics 67: 467-475.
34. White EW, Lumley T, Goodreau SM, Goldbaum G, Hawes SE, (2010) Stochastic models to demonstrate the effect of motivated testing on HIV incidence estimates using the serological testing algorithm for recent HIV seroconversion (STARHS). Sexually transmitted infections 86: 506-511.
35. Remis RS, Palmer RW, (2009) Testing bias in calculating HIV incidence from the Serologic Testing Algorithm for Recent HIV Seroconversion. AIDS 23: 493-503.
36. Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, et al. (2009) Transmission of drug-resistant HIV-1 is stabilizing in Europe. The Journal of infectious diseases 200: 1503-1508.
37. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action (2000) Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet 355: 1131-1137.
38. Bannister WP, Cozzi-Lepri A, Clotet B, Mocroft A, Kjaer J, et al. (2008) Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study. Journal of acquired immune deficiency syndromes 48: 324-333.
39. Cascade collaboration, (2003) Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 362: 1267-1274.
40. Perelson AS, Neuman AU, Markowitz M, Leonard JM, Ho DD, (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271: 1582-1586.
41. Roughgarden J, (1974) Population dynamics in a spatially varying environment: How population size "tracks" spatial variation in carrying capacity. American Naturalist 108: 649-664.
42. Meyer PS, Ausubel JH, (1999) Carrying capacity: a model with logistically varying limits. Technological Forecasting and Social Change 61: 209-214.
43. Hargrove J, Eastwood H, Mahiane G, van Schalkwyk C, (2012) How should we best estimate the mean recency duration for the BED method? PLoS ONE 7: e49661.
44. Alaeus A, Leitner T, Lidman K, Albert J, (1997) Most genetic subtypes of HIV-1 have entered Sweden. AIDS 11: 199-202.
45. Sabin CA, Schwenk A, Johnson MA, Gazzard B, Fisher M, et al. (2010) Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS 24: 723-727.
46. Antinori A, Coenen T, Costagiola D, Dedes N, Ellefson M, et al. (2011) Late presentation of HIV infection: a consensus definition. HIV medicine 12: 61-64.
47. Zoufaly A, an der Heiden M, Marcus U, Hoffmann C, Stellbrink H, et al. (2012) Late presentation for HIV diagnosis and care in Germany. HIV medicine 13: 172-181.
48. d'Arminio Monforte A, Cozzi-Lepri A, Girardi E, Castagna A, Mussini C, et al. (2011) Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome. Antiviral therapy 16: 1103-1112.
49. Centers for Disease Control and Prevention (CDC) (2009) Late HIV testing- 34 states, 1996-2005. MMWR Morbidity and mortality weekly report 58: 661-665.
50. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, et al. (2009) Effect of early versus deferred antiretroviral therapy for HIV on survival. The New England Journal of Medicine 360: 1815-1826.
51. Marks G, Crepaz N, Senterfitt JW, Janssen RS, (2005) Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. Journal of acquired immune deficiency syndromes 39: 446-453.
52. Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, et al. (2011) Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm(3): assessment of need following changes in treatment guidelines. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 53: 817-825.